Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data
Patients with psoriasis are more likely to experience depression and suicidality compared to non-psoriatic patients, though systemic therapies have been shown to improve depressive symptoms. It is unclear whether or not biologic or oral agents are more effective at improving such depressive symptoms...
Main Authors: | Samuel Yeroushalmi, Mimi Chung, Erin Bartholomew, Marwa Hakimi, John Koo |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2022.2152272 |
Similar Items
-
Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS)
by: Samuel Yeroushalmi, BS, et al.
Published: (2022-12-01) -
Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis
by: Congqin Chen, et al.
Published: (2023-01-01) -
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
by: Sandra Rodríguez, et al.
Published: (2020-08-01) -
Derivation and validation of a multivariable model to predict when primary care physicians prescribe antidepressants for indications other than depression
by: Wong J, et al.
Published: (2018-04-01) -
An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini
by: Alemayehu L. Duga, et al.
Published: (2022-11-01)